HepaRegeniX - Liver Diseases Face an Enormous Unmet Medical Need
Liver diseases are characterized by a gradual deterioration of the liver function, and, on a molecular level, by a reorganization and destruction of liver tissue. Several disease stages characterize the path from the healthy liver to a fully developed hepatocellular carcinoma (HCC). The causes for these circumstances include but are not limited to long-term external or internal risk factors.
-
Most popular related searches
Details
External risk factors include high-fat foods, excessive alcohol usage, toxins or infections. However, also autoimmune, genetic, and metabolic diseases can result in chronic liver dysfunction. 1,2
Millions of people are affected from these risk factors, for example:
- Nonalcoholic fatty liver disease (NAFLD) is increasingly recognized as a very wide-spread disease with estimates as high as 25 % of the population worldwide being affected. 3
- Risk factors for NAFLD and HCC include overweight, obesity and diabetes, affecting 2 billion and over 400 million adults, respectively.4
- Approximately 75 million people out of 2 billion regularly consuming alcohol worldwide are diagnosed with alcohol-abuse disorders and are at risk for alcoholic liver disease. 4
Alcoholic liver disease possibly being the chronic liver disease that is widest known.
Liver diseases today account for
- At least 250.000 patients suffering from an acute disease per year in EU5 and the U.S, and 700.000 patients from chronic liver diseases per year in EU5 and the U.S. 6
- 2 million or 3.5 % of worldwide deaths per year 4 with hepatocellular carcinoma as the most common primary liver cancer being considered fifth most common cancer and the third leading cause of cancer-related death in the United States. 7
These numbers illustrate the huge dimension of the unmet medical need in the liver field due to the lack of appropriate treatment options.
In order to fully meet this need, an unique and innovative approach is needed to treat a broad range of acute and chronic liver diseases, e.g. through MKK4 inhibition.
Customer reviews
No reviews were found for HepaRegeniX - Liver Diseases Face an Enormous Unmet Medical Need. Be the first to review!